Figure 1.

Median (25th, 75th percentile) change from baseline in 6MWT (A) distance and (B) fatigue over time. ^*Study visits up to and including day 253 occurred during the CS2 study, subsequent study visits occurred during the CS12 study. The day of the first study visit attended in the CS12 study depended upon the time between the end of the CS2 study and first dose in the CS12 study and the windowing of study visits described as follows. Median (range) time from the end of the CS2 study to first dose in the CS12 study was 118.0 (19–233) days. ^†Study days were derived from the first day of CS2 dosing for all CS2 and CS12 study visits and were assigned visit days as follows: study visits that took place >50 and ≤131 days from the first dose in the CS2 study were labeled day 92, visits >131 and ≤211 days from the first dose in CS2 were labeled day 169, those >211 and ≤302 days were labeled day 253, those >302 and ≤400 days were labeled day 350, and study visits >X − 50 to ≤X + 50 were labeled day X (starting at day 450 and increasing by 100 until day 1050), times between visit days were not equal, but were similar. 6MWT, 6‐minute walk test